The Digital Therapeutics Evidence Gap: What FDA Authorization Actually Required
Dr. Dereck Mush, MD, MBA
Peptone
Designs therapeutic proteins using biophysics and advanced computational modeling.
What they do
Peptone focuses on developing therapeutics for intrinsically disordered proteins. By combining advanced biophysical techniques with generative machine learning, they help pharmaceutical researchers design stable proteins to target diseases that lack traditional structured drug targets.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein therapeutics
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2016
- Total funding
- $40M raised
Notable investors: F-Prime Capital, Bessemer Venture Partners, Hoxton Ventures, dRx Capital.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA
State Medicaid programmes are quietly becoming a testing ground for digital therapeutics coverage
Dr. Dereck Mush, MD, MBA